Suchergebnisse - "Monk, Bradley J"

PubPharm (635)

1

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma : rationale, methods, and trial design

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Vergote, I. | Perez Fidalgo, A. | Valabrega, G. | +18

2

Immunotherapy plus chemoradiotherapy in cervical cancer management

enthalten in: Lancet (London, England) | 2024

von Tewari, K. | Monk, B.

3

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Hertz, D. | Joerger, M. | Bang, Y. | +8

4

Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma : NRG Oncology/GOG Study 279

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Horowitz, N. | Deng, W. | Peterson, I. | +14

5

Mirvetuximab soravtansine-gynx : first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Bogani, G. | Coleman, R. | Vergote, I. | +8

6

Reply to P.-H. Luo et al

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Monk, B. | Colombo, N. | Tewari, K. | +3

7

Progression-free survival and safety at 3.5 years of follow-up : results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

enthalten in: Future oncology (London, England) | 2024

von González-Martín, A. | Pothuri, B. | Vergote, I. | +15

8

CALLA trial : immunotherapy in locally advanced cervical cancer - Authors' reply

enthalten in: The Lancet. Oncology | 2024

von Monk, B. | Mayadev, J.

9

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

enthalten in: Gynecologic oncology reports | 2024

von Rimel, B. | Chase, D. | Perhanidis, J. | +9

10

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study

enthalten in: Gynecologic oncology | 2024

von Chan, J. | Tian, C. | Kesterson, J. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[64]